MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Acute Myeloid Leukemia, Myelodysplasia-Related
- Myelodysplastic Syndrome
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- National Cancer Institute (NCI)
- Enrolment target
- 2,000
- Started
- 18 June 2024
- Main results due
- 15 May 2029
- Study sites
- 350
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS. * Participants must be \>= 18 years of age. * Participants must not have received prior anti-cancer therapy for AML or MDS. * Note: Hydroxyurea to control the white blood cell count (WBC) is allowed. * Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction. * Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure. * Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment. * Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy * Note: active hormonal therapy is allowed * Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration. * Participants must agree to have translational medicine specimens submitted. * Participants must be offered the opportunity to participate in specimen banking. * Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP. * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. * Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system. * The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.
What this study is about
In the sponsor’s own words, from the registry.
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Study sites(350)
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona, United States
Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
Active, not recruiting
Kaiser Permanente Dublin
Dublin, California, United States
Recruiting
Kaiser Permanente-Fremont
Fremont, California, United States
Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California, United States
Recruiting
Kaiser Permanente-Fresno
Fresno, California, United States
Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
Recruiting
Tibor Rubin VA Medical Center
Long Beach, California, United States
Active, not recruiting
Cedars-Sinai Medical Center
Los Angeles, California, United States
Recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California, United States
Recruiting
Kaiser Permanente-Modesto
Modesto, California, United States
Recruiting
Kaiser Permanente-Oakland
Oakland, California, United States
Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States
Recruiting
Kaiser Permanente-Roseville
Roseville, California, United States
Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California, United States
Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California, United States
Recruiting
Kaiser Permanente-San Francisco
San Francisco, California, United States
Recruiting
UCSF Medical Center-Parnassus
San Francisco, California, United States
Recruiting
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California, United States
Recruiting
Kaiser Permanente San Leandro
San Leandro, California, United States
Recruiting
Kaiser San Rafael-Gallinas
San Rafael, California, United States
Recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California, United States
Recruiting
Kaiser Permanente-Santa Rosa
Santa Rosa, California, United States
Recruiting
Kaiser Permanente-South San Francisco
South San Francisco, California, United States
Recruiting
Kaiser Permanente-Vallejo
Vallejo, California, United States
Recruiting
Kaiser Permanente-Walnut Creek
Walnut Creek, California, United States
Recruiting
Yale University
New Haven, Connecticut, United States
Recruiting
Veterans Affairs Connecticut Healthcare System-West Haven Campus
West Haven, Connecticut, United States
Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida, United States
Recruiting
Mayo Clinic in Florida
Jacksonville, Florida, United States
Recruiting
Miami Cancer Institute
Miami, Florida, United States
Recruiting
Memorial Hospital West
Pembroke Pines, Florida, United States
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Recruiting
Phoebe Putney Memorial Hospital
Albany, Georgia, United States
Recruiting
Augusta University Medical Center
Augusta, Georgia, United States
Recruiting
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, United States
Recruiting
Straub Clinic and Hospital
Honolulu, Hawaii, United States
Recruiting
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, United States
Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, United States
Recruiting
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, United States
Recruiting
Pali Momi Medical Center
‘Aiea, Hawaii, United States
Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho, United States
Recruiting
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States
Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, United States
Recruiting
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho, United States
Recruiting
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho, United States
Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, United States
Recruiting
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho, United States
Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, United States
Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho, United States
Recruiting
Advocate Outpatient Center - Aurora
Aurora, Illinois, United States
Recruiting
Advocate Good Shepherd Hospital
Barrington, Illinois, United States
Recruiting
OSF Saint Joseph Medical Center
Bloomington, Illinois, United States
Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois, United States
Recruiting
Showing 60 of 350 sites — filter to narrow it down. 340 of the 350 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT05564390. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me